mDCF

DRUG2 trials

Sponsors

Jagiellonian University, GERCOR - Multidisciplinary Oncology Cooperative Group

Conditions

Anal CancerHER2 Negative Gastric Cancer

Phase 2

A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

CompletedNCT03519295

GERCOR - Multidisciplinary Oncology Cooperative GroupAnal Cancer

Start: 2018-07-03End: 2023-09-20Updated: 2025-06-27

Phase 3

Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma

CompletedNCT02445209

Jagiellonian UniversityHER2 Negative Gastric Cancer

Start: 2010-09-30End: 2014-02-28Updated: 2015-05-15

Related Papers

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

2024-04-0113 citations

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders

Journal for ImmunoTherapy of Cancer2024-01-0110 citations

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

Frontiers in Oncology2022-08-248 citations

Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.

Journal of Clinical Oncology2022-06-0117 citations

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

BMC Cancer2020-04-2527 citations

Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.

2015-09-0921 citations